Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,948 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.
Rastogi A, Ali A, Tan SH, Banerjee S, Chen Y, Cullen J, Xavier CP, Mohamed AA, Ravindranath L, Srivastav J, Young D, Sesterhenn IA, Kagan J, Srivastava S, McLeod DG, Rosner IL, Petrovics G, Dobi A, Srivastava S, Srinivasan A. Rastogi A, et al. Among authors: srinivasan a. Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126. Genes Cancer. 2016. PMID: 28191285 Free PMC article.
Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer.
Rastogi A, Tan SH, Mohamed AA, Chen Y, Hu Y, Petrovics G, Sreenath T, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA, Srivastava S, Dobi A, Srinivasan A. Rastogi A, et al. Among authors: srinivasan a. Genes Cancer. 2014 Jul;5(7-8):273-84. doi: 10.18632/genesandcancer.25. Genes Cancer. 2014. PMID: 25221645 Free PMC article.
ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity.
Rastogi A, Tan SH, Banerjee S, Sharad S, Kagan J, Srivastava S, McLeod DG, Srivastava S, Srinivasan A. Rastogi A, et al. Among authors: srinivasan a. Monoclon Antib Immunodiagn Immunother. 2014 Aug;33(4):201-8. doi: 10.1089/mab.2014.0026. Monoclon Antib Immunodiagn Immunother. 2014. PMID: 25170998
Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.
He J, Schepmoes AA, Shi T, Wu C, Fillmore TL, Gao Y, Smith RD, Qian WJ, Rodland KD, Liu T, Camp DG 2nd, Rastogi A, Tan SH, Yan W, Mohamed AA, Huang W, Banerjee S, Kagan J, Srivastava S, McLeod DG, Srivastava S, Petrovics G, Dobi A, Srinivasan A. He J, et al. Among authors: srinivasan a. J Transl Med. 2015 Feb 12;13:54. doi: 10.1186/s12967-015-0418-z. J Transl Med. 2015. PMID: 25889691 Free PMC article.
Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.
Mohamed AA, Tan SH, Xavier CP, Katta S, Huang W, Ravindranath L, Jamal M, Li H, Srivastava M, Srivatsan ES, Sreenath TL, McLeod DG, Srinivasan A, Petrovics G, Dobi A, Srivastava S. Mohamed AA, et al. Among authors: srinivasan a. Mol Cancer Res. 2017 Oct;15(10):1308-1317. doi: 10.1158/1541-7786.MCR-17-0058. Epub 2017 Jun 12. Mol Cancer Res. 2017. PMID: 28607007 Free PMC article.
Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence.
Yan W, Jamal M, Tan SH, Song Y, Young D, Chen Y, Katta S, Ying K, Ravindranath L, Woodle T, Kohaar I, Cullen J, Kagan J, Srivastava S, Dobi A, McLeod DG, Rosner IL, Sesterhenn IA, Srinivasan A, Srivastava S, Petrovics G. Yan W, et al. Among authors: srinivasan a. Oncotarget. 2019 Nov 5;10(60):6466-6483. doi: 10.18632/oncotarget.27294. eCollection 2019 Nov 5. Oncotarget. 2019. PMID: 31741711 Free PMC article.
Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer.
Kiebish MA, Cullen J, Mishra P, Ali A, Milliman E, Rodrigues LO, Chen EY, Tolstikov V, Zhang L, Panagopoulos K, Shah P, Chen Y, Petrovics G, Rosner IL, Sesterhenn IA, McLeod DG, Granger E, Sarangarajan R, Akmaev V, Srinivasan A, Srivastava S, Narain NR, Dobi A. Kiebish MA, et al. Among authors: srinivasan a. J Transl Med. 2020 Jan 7;18(1):10. doi: 10.1186/s12967-019-02185-y. J Transl Med. 2020. PMID: 31910880 Free PMC article.
Prognostic features of Annexin A2 expression in prostate cancer.
Tan SH, Young D, Chen Y, Kuo HC, Srinivasan A, Dobi A, Petrovics G, Cullen J, Mcleod DG, Rosner IL, Srivastava S, Sesterhenn IA. Tan SH, et al. Among authors: srinivasan a. Pathology. 2021 Feb;53(2):205-213. doi: 10.1016/j.pathol.2020.07.006. Epub 2020 Sep 20. Pathology. 2021. PMID: 32967771 Free PMC article.
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
Kiebish MA, Tekumalla P, Ravipaty S, Dobi A, Srivastava S, Wu W, Patil S, Friss T, Klotz A, Srinivasan A, Cullen J, Rosner IL, Ali A, Laszlo S, Petrovic M, Fleshner N, Garren J, Miller G, Mahaveer Chand N, Rodrigues LO, Granger E, Kellogg MD, Luan S, Diamandis E, Akmaev VR, Sarangarajan R, Bountra C, Freedland SJ, McLeod DG, Narain NR. Kiebish MA, et al. Among authors: srinivasan a. Sci Rep. 2021 Jul 23;11(1):15052. doi: 10.1038/s41598-021-94438-4. Sci Rep. 2021. PMID: 34302010 Free PMC article.
1,948 results